2-(pyridin-2-ylmethyl)isoindoline-1,3-dione | 34403-37-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-(pyridin-2-ylmethyl)isoindoline-1,3-dione
• 英文别名: 2-(pyridin-2-ylmethyl)-1H-isoindole-1,3(2H)-dione；2-(pyridin-2-ylmethyl)isoindole-1,3-dione
• CAS: 34403-37-7
• 化学式: C₁₄H₁₀N₂O₂
• 分子量: 238.246
• InChiKey: VLXJCTIPUCCTKN-UHFFFAOYSA-N

物化性质

• 熔点：
  124 °C
• 沸点：
  405.4±28.0 °C(Predicted)
• 密度：
  1.368±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  50.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(pyridin-2-ylmethyl)isoindoline-1,3-dione 在 potassium hydroxide 作用下， 以 乙醇 为溶剂， 反应 24.0h， 以91%的产率得到邻苯二甲酸
  参考文献：
  名称：

  N-（吡啶-2-基甲基）苯甲酰胺用TFBen作为CO源的钴催化羰基合成。

  摘要：

  已经开发了由N-（吡啶-2-基甲基）苯甲酰胺钴催化的邻苯二甲酰亚胺基序的直接羰基合成。通过使用2-吡啶甲基胺作为有效的导向基团和苯-1,3,5-三甲酸三甲酸酯（TFBen）作为常规的CO替代物，可以中等至极好的收率（高达98％）获得各种邻苯二甲酰亚胺衍生物。

  DOI：

  10.1021/acs.joc.9b01890
• 作为产物：
  描述：

  邻苯二甲酸单甲酯 在 氯化亚砜 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 生成 2-(pyridin-2-ylmethyl)isoindoline-1,3-dione
  参考文献：
  名称：

  New anti-inflammatory N-pyridinyl(alkyl)phthalimides acting as tumour necrosis factor-α production inhibitors

  摘要：

  This paper describes the synthesis of N-pyridinyl(alkyl)phthalimides related to N-phenyl-4,5,6,7-tetrafluorophthalimides known to be inhibitors of tumour necrosis factor-alpha (TNF alpha) production. Pharmacomodulation at the phthalimidic nitrogen led to the selection of two pharmacophoric fragments (2,4-lutidinyl and beta -picolyl), allowing significant inhibition of TNF alpha production (compounds 12 and 17). Variation of the substituents linked to the homocycle of their phthalimide scaffold indicated that high (TNF alpha production) inhibitory potency could be achieved, notably by 5-fluoro, 4- or 5-nitro, 5-amino and especially tetrafluoro substitution. The most active compound, N-(pyridin-3-ylmethyl)-4,5,6,7-tetrafluorophthalimide (32) (84% inhibition at 10 muM), also produced an anti-oedematous effect in the PMA-induced mouse-ear swelling test. Although less active than dexamethasone, it exerted a marked reduction in ear thickness after oral administration (63% vs. 85% for dexamethasone at 0.2 mM kg(-1)) and remained efficient after topical application (46% vs. 96% for the dexamethasone). It also induced potent inhibition in the rat carrageenan foot oedema test with an ID50 (0.14 muM kg(-1)) comparable with that of N-(2,6-diisopropylphenyl)phthalimide (4) (0.15 muM kg(-1)). (C) 2001 Editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(01)01254-5

文献信息

• H-β-zeolite catalyzed transamidation of carboxamides, phthalimide, formamides and thioamides with amines under neat conditions
  作者：Sadu Nageswara Rao、Darapaneni Chandra Mohan、Subbarayappa Adimurthy

  DOI：10.1039/c5ra16933j

  日期：——

  Efficient transamidation of unactivated carboxamides, phthalimides, formamides and thioamides with amines under solvent-free conditions using H-β-zeolite as a green and recyclable heterogeneous catalyst is described. Easy work up, high purity of the products, recyclability and environmentally-friendly nature of the catalyst are the attractive features of the present methodology. This is the first report

  描述了在无溶剂条件下使用H-β沸石作为绿色可循环使用的非均相催化剂，将未活化的羧酰胺，邻苯二甲酰亚胺，甲酰胺和硫代酰胺与胺进行有效的氨基转移。易于加工，产物的高纯度，催化剂的可回收性和对环境友好的性质是本方法的吸引人的特征。这是在异质条件下硫酰胺转氨作用的第一份报告。
• Unmasking Amides: Ruthenium-Catalyzed Protodecarbonylation of N-Substituted Phthalimide Derivatives
  作者：Yu-Chao Yuan、Raghu Kamaraj、Christian Bruneau、Thierry Labasque、Thierry Roisnel、Rafael Gramage-Doria

  DOI：10.1021/acs.orglett.7b03278

  日期：2017.12.1

  The unprecedented transformation of a wide range of synthetically appealing phthalimides into amides in a single-step operation has been achieved in high yields and short reaction times using a ruthenium catalyst. Mechanistic studies revealed a unique, homogeneous pathway involving five-membered ring opening and CO2 release with water being the source of protons.

  使用钌催化剂，以高收率和较短的反应时间实现了单步操作中各种合成吸引力的邻苯二甲酰亚胺前所未有的转化为酰胺。机理研究表明，独特的均质途径涉及五元环的打开和CO 2的释放，其中水是质子的来源。
• DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS
  申请人：Rutgers, The State University of New Jersey

  公开号：US20180148408A1

  公开（公告）日：2018-05-31

  A method of identifying compounds as direct inhibitors of Keap1-Nrf2 interaction through high-throughput screening and lead development. The direct inhibitors of Keap1-Nrf2 interaction are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential drug candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, and Parkinson's. Novel compounds are identified and methods of preventing or treating diseases or conditions related to Keap1-Nrf2 interaction activity by use of the novel compounds identified or compositions containing such compounds are also disclosed.

  通过高通量筛选和引物开发的方法，识别化合物作为Keap1-Nrf2相互作用的直接抑制剂。Keap1-Nrf2相互作用的直接抑制剂比现有的间接抑制剂更具特异性，不受各种不良影响，并且是化学预防和治疗各种涉及氧化应激和/或炎症的疾病或症状的潜在药物候选者，包括但不限于癌症、糖尿病、阿尔茨海默病和帕金森病。还公开了识别新化合物以及使用所识别的新化合物或含有这些化合物的组合物来预防或治疗与Keap1-Nrf2相互作用活性相关的疾病或症状的方法。
• An Efficient Heterobimetallic Lanthanide Alkoxide Catalyst for Transamidation of Amides under Solvent-Free Conditions
  作者：Hongting Sheng、Ruijie Zeng、Wenjuan Wang、Shuwen Luo、Yan Feng、Jing Liu、Weijian Chen、Manzhou Zhu、Qingxiang Guo

  DOI：10.1002/adsc.201600373

  日期：2017.1.19

  lanthanide catalysts showed high catalytic activity and a wide scope of substrates with good to excellent yields under solvent‐free conditions. Efficient activation of the transamidation can be realized by the above complexes acting as cooperative acid–base bifunctional catalysts, which are proposed to be responsible for the higher reactivity in comparison with simple monometallic catalysts.

  已经开发出一种实用的杂双金属镧系元素催化的伯，仲和叔酰胺与脂肪族和芳香族胺的酰胺化反应。该方法还应用于弱反应性硫代酰胺，以证明其多功能性和广泛的底物范围。杂双金属镧系元素催化剂在无溶剂条件下显示出高催化活性和多种底物，收率良好至优异。可以通过上述配合物作为酸基双官能催化剂，来实现转酰胺基的有效活化，与简单的单金属催化剂相比，这些络合物被认为具有更高的反应活性。
• 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1424336A1

  公开（公告）日：2004-06-02

  This invention provides a compound represented by the formula (I) : wherein R1 is a hydrogen atom, a halogen atom, hydroxy, nitro, optionally halogenated alkyl, alkoxy optionally having substituents, acyl or amino optionally having substituents; R2 is pyridyl, furyl, thienyl, pyrrolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, tetrahydroquinolyl or thiazolyl, each of which may have substituents; n is 1 or 2; or a salt. And this invention provides a safe pharmaceutical comprising the compound of the formula (I) , which has an excellent apoptosis inhibitory effect and MIF binding effect, for preventing and/or treating heart disease, nervous degenerative disease, cerebrovascular disease, central nervous infectious disease, traumatorathy, demyelinating disease, bone and articular disease, kidney disease, liver disease, osteomyelodysplasia, AIDS, cancer, and the like.

  这项发明提供了一种由以下式（I）表示的化合物： 其中R1是氢原子、卤素原子、羟基、硝基、可选择具有卤素取代基的烷基、可选择具有取代基的烷氧基、酰基或氨基； R2是吡啶基、呋喃基、噻吩基、吡咯基、喹啉基、吡嗪基、嘧啶基、吡啶并嘧啶基、吲哚基、四氢喹啉基或噻唑基，每种基团可能具有取代基； n为1或2；或其盐。该发明提供了一种安全的药物，包括具有优异的凋亡抑制作用和MIF结合作用的式（I）化合物，用于预防和/或治疗心脏病、神经退行性疾病、脑血管疾病、中枢神经感染性疾病、创伤病变、脱髓鞘疾病、骨骼和关节疾病、肾脏疾病、肝脏疾病、骨髓发育不良、艾滋病、癌症等。